Stay Informed on Corporate Sustainability

Explore industry news, insights, and updates from the Pharma Industry Awards.

Sort by

Accro Bioscience Grants Fosun Pharma Exclusive Rights for TYK2/JAK1 Inhibitor in Greater China

Author: Contract Pharma

Accro Bioscience, a biotechnology company, has entered into an agreement granting Fosun Pharma exclusive rights to develop, manufacture, and commercialize its TYK2/JAK1 inhibitor, AC-201, in Greater China, encompassing Chinese Mainland, Hong Kong SAR, and Macau SAR. Accro will retain global rights for AC-201 outside these regions.

Irish pharma risks hostage situation as EU weighs DSA and Ukraine criticism

Author: EURACTIV

The US is losing patience with the EU on digital policy and its Ukraine long game; Ireland’s pharma negotiations could be hostage to a wider standoff

India eyes Russia, Brazil, Netherlands for pharma export growth as US tariffs concerns linger

Author: Yahoo Finance

India plans to increase pharmaceutical exports to Russia, the Netherlands and Brazil, according to two industry sources aware of the matter, aiming to expand its presence beyond the United States, its largest market, amid tariff-related concerns.

Regeneron preps filings for myasthenia gravis drug

Author: Pharmaphorum

Regeneron could be just a few months away from filing for approval of a therapy for the neuromuscular disorder generalised myasthenia gravis (gMG), cemdisiran, which can be dosed just four times a year.

Enduring Progress

Author: Jed Nykolle Harme

The pharmaceutical and life sciences sector continues to navigate an era defined by innovation, scrutiny, and the recalibration of trust.

Pharma ExCellThera's novel blood cancer stem cell therapy Zemcelpro earns EU nod

Author: Fierce Pharma

A new treatment option for certain patients with blood cancers has passed muster with the European Commission (EC).

Amylyx to stop development of rare brain disorder drug after trial failure

Author: REUTERS

Aug 27 (Reuters) - Amylyx Pharmaceuticals (AMLX.O), said on Wednesday it will stop development of its experimental drug for a rare brain disorder after it failed to improve symptoms in patients during a mid-stage trial.

Exclusive: Indonesia will give food companies two years to meet new labelling rules

Author: REUTERS

Indonesia will set a deadline of two years for food and beverage companies to meet new labelling norms for products high in salt, sugar or fat, a government official told Reuters, a move that spells more delays in efforts to curb fast-rising obesity.

EVERSANA buys digital drug-price marketplace firm Waltz Health

Author: Pharmaphorum

Pharma commercialisation services provider EVERSANA (pharmaphorum's parent company) has acquired Waltz Health, a Chicago digital health company offering AI-driven marketplaces to lower overall drug costs. The terms of the deal were not disclosed.